Allele Inc. Files Patent Application for Nanoparticles conjugated to specific Nucleotide Sequences

On March 31, 2022, pre-exam processing began for Allele’s recent provisional patent filing with the USPTO, #63/362298. The application specifically cites seven genes whose related nucleotide sequences are to be conjugated to nanoparticles. In primary embodiments, the nanoparticles are intended to be used to recognize specific cell-free RNA (cfRNA) sequences in a sample in order to recognize warning signs of complications, including preeclampsia, before a patient is symptomatic. Read more about Allele’s work in preeclampsia diagnostics.

The patent also describes specific uses in its detailed description of claimed IP, including LFA devices and theranostics facilitated through nanoparticle consumption, such as MRI assessments. Read more about Allele’s recent patent filing with regard to its patent-pending LFA device using nanoparticles to assess for preeclampsia. The patent describes methods of conjugation, potential biosensors, and examples of nanoparticles that can be utilized—ranging from noble metal nanoparticles to lipid biomolecules.

The filing is not yet available to the public due to its provisional status, but Allele intends to file a corresponding nonprovisional utility patent within the 12-month applicable period. Recent breakthrough research by Moufarrej et al. spurred this innovation.

Allele Inc. looks forward to continuing this research and bettering patient outcomes through nanobiotechnology.